Production (Stage)
Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 471.10K | 381.80K | 255.40K | 234.30K | 269.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.26M | 1.13M | 560.50K | -179.90K | 347.70K |
| Operating Income | -2.26M | -1.13M | -560.50K | 179.90K | -347.70K |
| Income Before Tax | -2.06M | 35.40K | -549.40K | 157.10K | -425.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.06M | 35.40K | -549.40K | 157.10K | -425.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.06M | 35.40K | -549.40K | 157.10K | -425.90K |
| EBIT | -2.26M | -1.13M | -560.50K | 179.90K | -347.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.29 | 0.01 | -0.12 | 0.04 | -0.10 |
| Normalized Basic EPS | -0.18 | 0.00 | -0.08 | 0.02 | -0.06 |
| EPS Diluted | -0.29 | 0.01 | -0.12 | 0.04 | -0.10 |
| Normalized Diluted EPS | -0.18 | 0.00 | -0.08 | 0.02 | -0.06 |
| Average Basic Shares Outstanding | 7.04M | 6.17M | 4.47M | 4.46M | 4.46M |
| Average Diluted Shares Outstanding | 7.04M | 6.64M | 4.47M | 4.65M | 4.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |